Utmattelse ved inflammatorisk tarmsykdom

Grimstad, Tore; Norheim, Katrine Brække

doi:10.4045/tidsskr.16.0134

Cited by 7 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that various factors may contribute to experiencing fatigue in patients with IMIDs, such as the disease itself and behavioural and psychological factors [3][4][5][6][7]. Multimorbidity, pain, depression and disability have been associated with fatigue in rheumatic diseases [3,4,[8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

Lint

Jessurun

Tas³

et al. 2023

BioDrugs

View full text Add to dashboard Cite

Background Fatigue is a common problem in immune-mediated inflammatory disease (IMID) patients, significantly impacting their quality of life. Objectives In this study, we describe the pattern and characteristics of fatigue as a patient-reported adverse drug reaction (ADR) of biologics, and compared patient and treatment characteristics with patients reporting other ADRs or no ADRs. Methods In this cohort event monitoring study, the description and characteristics of fatigue reported as a possible ADR in the Dutch Biologic Monitor were assessed and analysed for commonly recurring themes or patterns. Baseline and treatment characteristics of patients with fatigue and patients reporting other ADRs or no ADRs were compared. Results Of 1382 participating patients, 108 patients (8%) reported fatigue as an ADR of a biologic. Almost half of these patients (50 patients, 46%) described episodes of fatigue during or shortly after biologic injection, which often recurred following subsequent injections. Patients with fatigue were significantly younger than patients with other ADRs or patients without ADRs (median age for patients with fatigue, 52 years; median age for patients with other ADRs, 56 years; and median age for patients without ADRs, 58 years); significantly more often smoked (25% vs. 16% and 15%); used infliximab (22% vs. 9% and 13%), rituximab (9% vs. 3% and 1%) or vedolizumab (6% vs. 2% and 1%); and significantly more often had Crohn's disease (28% vs. 13% and 13%) and other comorbidities (31% vs. 20% and 15%). Patients with fatigue significantly less frequently used etanercept (12% vs. 29% and 34%) or had rheumatoid arthritis (30% vs. 45% and 43%). Conclusions IMID patients may experience fatigue as a postdosing effect of biologics. Key PointsFatigue is a common complaint among patients with immune-mediated inflammatory diseases (IMIDs), but it is not well known as an adverse drug reaction (ADR) of biologics.In this study, fatigue was the most frequently reported ADR of biologics by patients with IMIDs, and many of these patients described a pattern of recurring fatigue after biologic injection.Evaluating the clinical pattern of fatigue may aid in understanding the potential contribution of a biologic in patients experiencing fatigue.

show abstract

Section: Introductionmentioning

confidence: 99%

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

Lint

Jessurun

Tas³

et al. 2023

BioDrugs

View full text Add to dashboard Cite

show abstract

Psychosomatik

Winter¹

2023

Pflege Bei Chronisch-Entzündlichen Darmerkrankungen

View full text Add to dashboard Cite

Mindfulness-Based Cognitive Therapy for Fatigue in Patients with Inflammatory Bowel Disease: Results of a Randomized Controlled Trial

et al. 2023

View full text Add to dashboard Cite

Objectives Fatigue is a prevalent and burdensome problem in patients with inflammatory bowel disease (IBD), even when the disease is in remission. Evidence-based psychological interventions for managing IBD-related fatigue are still lacking. This study aimed to examine the efficacy of Mindfulness-Based Cognitive Therapy (MBCT) for reducing fatigue in patients with IBD in remission. Method A two-arm multicenter randomized controlled trial was conducted in 113 IBD outpatients in remission with elevated levels of fatigue (i.e., Checklist Individual Strength — subjective fatigue ≥ 27). Patients were randomly assigned to an 8-week MBCT program (n = 56) or a waiting-list condition (n = 57). All participants completed questionnaires at baseline and directly post-intervention. The primary outcome was fatigue, assessed with the Checklist Individual Strength-20. Secondary outcomes included fatigue interference in daily life, depression, anxiety, and IBD-specific quality of life. Analysis of covariance (ANCOVA) was performed to examine treatment outcomes. Results Intention-to-treat analyses showed significant reductions in the subjective experience of fatigue in patients receiving MBCT, compared to the waiting-list control condition (p = 0.03; Cohen’s d = 0.46; clinically relevant improvement in 36% vs. 10%). No significant effects were found on other fatigue aspects or secondary outcomes. Conclusions An 8-week MBCT group program effectively reduced the subjective experience of fatigue in patients with IBD in remission. Results do not support effects for other aspects of fatigue or secondary outcomes. Preregistration ClinicalTrials.gov Identifier: NCT03162575.

show abstract

Utmattelse ved inflammatorisk tarmsykdom

Cited by 7 publications

References 43 publications

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

Psychosomatik

Mindfulness-Based Cognitive Therapy for Fatigue in Patients with Inflammatory Bowel Disease: Results of a Randomized Controlled Trial

Contact Info

Product

Resources

About